Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Burlington, Vermont 05401


Purpose:

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ixabepilone in treating patients who have relapsed or refractory lymphoproliferative disorders.


Study summary:

OBJECTIVES: Primary - Determine the frequency and duration of complete and partial response rates for patients with relapsed or refractory indolent lymphoproliferative disorders treated with ixabepilone. Secondary - Determine the time to progression and overall survival of patients treated with this drug. - Determine the toxicity of this drug in these patients. OUTLINE: This is an open-label study. Patients receive ixabepilone IV over 1 hour weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1-1.5 years.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed relapsed/recurrent or refractory indolent lymphoproliferative disorder of 1 of the following types: - Chronic lymphocytic leukemia - Absolute lymphocytosis greater than 5,000/mm^3 - B-cell phenotype (CD 19, 20, or 23 positive) with more than 30% bone marrow lymphocytes - B-cell small lymphocytic lymphoma - Marginal zone B-cell lymphoma - Grade I-III follicle center cell lymphoma - Waldenstrom's macroglobulinemia - Mantle cell lymphoma - At least 1 unidimensionally measurable lesion for patients with non-Hodgkin's lymphoma - At least 2 cm by conventional techniques - No active brain metastases - Treated CNS disease allowed PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 60-100% Life expectancy - At least 3 months Hematopoietic - Absolute neutrophil count ≥ 1,000/mm^3 (500/mm^3 if there is lymphomatous involvement of the bone marrow) - Platelet count ≥ 50,000/mm^3 Hepatic - Bilirubin ≤ 1.5 times upper limit of normal (ULN) - AST or ALT ≤ 2.5 times ULN (4 times ULN if there is liver involvement) Renal - Creatinine ≤ 2 times ULN OR - Creatinine clearance ≥ 50 mL/min Cardiovascular - No history of orthostatic hypotension - No myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 3 months - No New York Heart Association class III or IV congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - No uncontrolled hypertension requiring manipulation of antihypertensive medications - No evidence of any of the following by echocardiogram: - Acute ischemia - Significant conduction abnormality - Bifascicular block - 2^nd- or 3^rd-degree atrioventricular block Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - No other immunodeficiency - No known severe hypersensitivity reaction to agents containing Cremophor EL - No ongoing or active infection - Febrile episodes up to 38.5° Celsius allowed in the absence of infection - No other concurrent uncontrolled illness that would preclude study participation - No psychiatric illness or social situation that would preclude study compliance - No preexisting grade II or greater sensory neuropathy PRIOR CONCURRENT THERAPY: Biologic therapy - At least 3 months since prior monoclonal antibodies (unless there is clearly documented evidence of disease progression after therapy) - At least 3 months since prior radioimmunotherapy - No prior allogeneic bone marrow transplantation Chemotherapy - At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin, nitrosoureas, or carmustine) and recovered - No more than 4 prior chemotherapy regimens (including high-dose chemotherapy [HDC] for patients with relapsed disease > 100 days after completion of HDC) - Cytoreduction plus HDC is considered 1 chemotherapy regimen - No other concurrent chemotherapy Endocrine therapy - At least 7 days since prior steroids Radiotherapy - More than 3 weeks since prior radiotherapy and recovered - No concurrent radiotherapy Surgery - More than 4 weeks since prior major surgery Other - Use of antibiotics for marginal zone lymphoma does not count as a prior therapy - No other concurrent investigational agents - No other concurrent anticancer therapy


NCT ID:

NCT00052572


Primary Contact:

Study Chair
Owen A. O'Connor, MD, PhD
Memorial Sloan-Kettering Cancer Center


Backup Contact:

N/A


Location Contact:

Burlington, Vermont 05401
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.